We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+11.46%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$48.6M
Cap. Flow
+$29.5M
Cap. Flow %
11.97%
Top 10 Hldgs %
69.44%
Holding
26
New
5
Increased
10
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.5M
2
DYN icon
Dyne Therapeutics
DYN
+$16M
3
PCVX icon
Vaxcyte
PCVX
+$10.2M
4
LENZ
LENZ Therapeutics
LENZ
+$9.31M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$6.67M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$26.2M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.95M
3
IRON icon
Disc Medicine
IRON
+$5.73M
4
MRUS
Merus
MRUS
+$4.65M
5
SLN
Silence Therapeutics
SLN
+$2.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
26
DELISTED
Inozyme Pharma
INZY
– –
-499,254
Closed -$454K
1
2

Similar funds

TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.32% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $549M AUM 24.44% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Saturn V Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Saturn V Capital Management held 26 positions worth $247M, up 25% from $198M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Saturn V Capital Management deployed $29.5M of net new capital in Q2 2025, opening 5 new positions and adding to 10 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 206,952 shares worth $22M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $26.2M trimmed.

  • Saturn V Capital Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 206,952 shares worth $22M.
  • Saturn V Capital Management added most to Vaxcyte in Q2 2025, an estimated $10.2M increase.
  • Saturn V Capital Management's biggest Q2 2025 reduction was Ascendis Pharma A/S, cutting an estimated $26.2M.
  • Saturn V Capital Management fully exited Crinetics Pharmaceuticals in Q2 2025, selling an estimated $1.98M.
  • Saturn V Capital Management's ten largest holdings make up 69% of its $247M portfolio in Q2 2025.
  • Saturn V Capital Management opened 5 new positions and closed 2 in Q2 2025.
  • Saturn V Capital Management's portfolio value rose 25% quarter-over-quarter to $247M.

Based on Saturn V Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.